The weight-loss drug market is about to get even more crowded. Eli Lilly & Co (NYSE:LLY) stock is up 2.2% at $830.80, after a news release reported the company's weight-loss drug Zepbound rivaled Novo Nordisk's (NVO) Wegovy in a head-to-head trial. The treatment achieved an average weight loss of 20.2% at 72 weeks in adults with obesity without diabetes, while its rival managed 13.7%. Eli Lilly stock has been rebounding since its early-November nine-month lows, now headed for its sixth win in the last seven ...